Steven Adelsheim is a child/adolescent and adult psychiatrist who works to support community behavioral health partnerships locally, regionally, at the state level and nationally. Dr. Adelsheim has partnered in developing statewide mental health policy and systems, including those focused on school mental health, telebehavioral health, tribal behavioral health programs, and suicide prevention. For many years Dr. Adelsheim has been developing and implementing early detection/intervention programs for young people in school-based and primary care settings, including programs for depression, anxiety, prodromal symptoms of psychosis, and first episodes of psychosis. Dr. Adelsheim is also involved in the implementation of integrated behavioral health care models in primary care settings as well as the use of media to decrease stigma surrounding mental health issues.

Clinical Focus

  • Psychiatry

Academic Appointments

Administrative Appointments

  • Director of Community Partnerships, Stanford Department of Psychiatry and Behavioral Sciences (2013 - Present)

Honors & Awards

  • Norbert and Charlotte Rieger Service Program Award for Excellence, American Academy of Child and Adolescent Psychiatry (1999)
  • "Marketer of the Year” Award; “Childhood Revealed, New Mexico 2001”, New Mexico Chapter of the American Marketing Association (2002)
  • Highland Human Services Collaborative Award for Exemplary Dedication, Highland Human Services Collaborative; New Mexico Advocates for Children and Families (1998)
  • Juanita Evans Memorial Award, Center for School Mental Health, University of Maryland School of Medicine (2003)
  • Best Documentary and Best Writing-Programs, Documentaries or Magazines, “Coming Back”, Rocky Mountain SW Chapter; National Academy of Television Arts and Sciences; Clinical Editor (2005)
  • Irving Phillips Award for Prevention, American Academy of Child and Adolescent Psychiatry (2005)
  • Agnes Purcell McGavin Award for Prevention, American Psychiatric Association (2006)
  • Bronze World Medal; “Not in My Family”; Associate Producer, New York Festival (2006)
  • NAMI Exemplary Psychiatrist Award, National Alliance on Mental Illness (2009)
  • Sidney Berman Award for School-Based Study and Treatment of Learning Disorders and Mental Illness, American Academy of Child and Adolescent Psychiatry (2012)

Boards, Advisory Committees, Professional Organizations

  • Councilor at Large, American Academy of Child and Adolescent Psychiatry (2010 - 2013)
  • National Advisory Board, Robert Wood Johnson Foundation Local Funding Partners (2009 - Present)
  • Member, American College of Psychiatrists (2013 - Present)
  • Member, Adolescent Committee, American Academy of Child and Adolescent Psychiatry (2013 - Present)
  • Member, New Mexico Native American Suicide Prevention Workgroup and Clearinghouse (2011 - 2013)
  • Member, New Mexico State Workgroup on Child Psychopharmacology (2007 - 2013)
  • Co-Chair, Committee on Schools, American Academy of Child and Adolescent Psychiatry (2003 - 2010)
  • National Advisory Board, Robert Wood Johnson Foundation Early Detection and Intervention for the Prevention of Psychosis Program (2008 - 2010)
  • Associate Member, John D. and Katherine T. MacArthur Foundation Network on Mental Health Policy Research (2003 - 2009)
  • President, New Mexico Council on Child and Adolescent Psychiatry (2007 - 2008)
  • National Advisory Committee, Center for School Mental Health, University of Maryland Department of Psychiatry (2005 - Present)
  • Member, Committee on Telepsychiatry, American Academy of Child and Adolescent Psychiatry (2009 - 2011)
  • Commissioner, New Mexico Telehealth Commission (2005 - 2009)
  • Member, New Mexico Governor's Task Force on Compulsive Gambling (2005 - 2009)
  • Chair, New Mexico Child Fatality Review Suicide Review Panel (2005 - 2010)
  • Convener and Coordinator, New Mexico Governor's Task Force on Youth Suicide Prevention (2004 - 2005)
  • Member, New Mexico State Medicaid Advisory Committee (2003 - 2008)

Professional Education

  • Board Certification: Psychiatry, American Board of Psychiatry and Neurology (1991)
  • Board Certification: Child and Adolescent Psychiatry, American Board of Psychiatry and Neurology (1991)
  • Fellowship:University of New Mexico School of Medicine (1990) NM
  • Residency:University of New Mexico School of Medicine (1988) NM
  • Medical Education:University of Cincinnati College of Medicine (1985) OH
  • Board Certification, American Board of Psychiatry and Neurology, Child and Adolescent Psychiatry (1991)
  • Board Certification, American Board of Psychiatry and Neurology, General Psychiatry (1991)
  • Fellowship, University of New Mexico Health Sciences Center, Child and Adolescent Psychiatry (1990)
  • Residency, University of New Mexico health Sciences Center, General Psychiatry (1988)
  • MD, University of Cincinnati College of Medicine (1985)
  • BA, Harvard College, Psychology and Social Relations (1979)


All Publications

  • Clinical and Functional Outcomes After 2 Years in the Early Detection and Intervention for the Prevention of Psychosis Multisite Effectiveness Trial SCHIZOPHRENIA BULLETIN McFarlane, W. R., Levin, B., Travis, L., Lucas, F. L., Lynch, S., Verdi, M., Williams, D., Adelsheim, S., Calkins, R., Carter, C. S., Cornblatt, B., Taylor, S. F., Auther, A. M., McFarland, B., Melton, R., Migliorati, M., Niendam, T., Ragland, J. D., Sale, T., Salvador, M., Spring, E. 2015; 41 (1): 30-43


    To test effectiveness of the Early Detection, Intervention, and Prevention of Psychosis Program in preventing the onset of severe psychosis and improving functioning in a national sample of at-risk youth.In a risk-based allocation study design, 337 youth (age 12-25) at risk of psychosis were assigned to treatment groups based on severity of positive symptoms. Those at clinically higher risk (CHR) or having an early first episode of psychosis (EFEP) were assigned to receive Family-aided Assertive Community Treatment (FACT); those at clinically lower risk (CLR) were assigned to receive community care. Between-groups differences on outcome variables were adjusted statistically according to regression-discontinuity procedures and evaluated using the Global Test Procedure that combined all symptom and functional measures.A total of 337 young people (mean age: 16.6) were assigned to the treatment group (CHR + EFEP, n = 250) or comparison group (CLR, n = 87). On the primary variable, positive symptoms, after 2 years FACT, were superior to community care (2 df, p < .0001) for both CHR (p = .0034) and EFEP (p < .0001) subgroups. Rates of conversion (6.3% CHR vs 2.3% CLR) and first negative event (25% CHR vs 22% CLR) were low but did not differ. FACT was superior in the Global Test (p = .0007; p = .024 for CHR and p = .0002 for EFEP, vs CLR) and in improvement in participation in work and school (p = .025).FACT is effective in improving positive, negative, disorganized and general symptoms, Global Assessment of Functioning, work and school participation and global outcome in youth at risk for, or experiencing very early, psychosis.

    View details for DOI 10.1093/schbul/sbu108

    View details for Web of Science ID 000350057900012

    View details for PubMedID 25065017

  • From School Health to Integrated Health: Expanding Our Children's Public Mental Health System ACADEMIC PSYCHIATRY Adelsheim, S. 2014; 38 (4): 405-408


    There is a substantial unmet need for mental health and substance abuse services in the USA. In 2009, the Institute of Medicine recommended increased early identification and intervention for young people with mental, emotional, and behavioral disorders. With the expansion of integrated models in primary care settings, we now have the chance to improve outcomes for young people with mental health conditions, just as we have by improving the early identification and treatment of other preventable and/or treatable conditions such as obesity, asthma, or HIV. This is a moment of great opportunity to fundamentally change how young people access mental health care in our country. Through strategic integration of care, we can increase access to care for those who would not seek out mental health services because of the stigma or inconvenience of reaching out to a mental health provider; we can identify those who need care earlier and reduce the impact of mental illness on individuals, family, and community through early identification and treatment; and we can purposefully embed integration into provider training programs for both primary care and mental health providers to ensure sustainability.

    View details for DOI 10.1007/s40596-014-0174-z

    View details for Web of Science ID 000339803500004

    View details for PubMedID 24912970

  • Factor analysis of the Scale of Prodromal Symptoms: data from the Early Detection and Intervention for the Prevention of Psychosis Program. Early intervention in psychiatry Tso, I. F., Taylor, S. F., Grove, T. B., Niendam, T., Adelsheim, S., Auther, A., Cornblatt, B., Carter, C. S., Calkins, R., Ragland, J. D., Sale, T., McFarlane, W. R. 2014


    The Scale of Prodromal Symptoms (SOPS) was developed to identify individuals experiencing early signs of psychosis, a critical first step towards early intervention. Preliminary dimension reduction analyses suggested that psychosis-risk symptoms may deviate from the traditional symptom structure of schizophrenia, but findings have been inconsistent. This study investigated the phenomenology of psychosis risk symptoms in a large sample from a multi-site, national study using rigorous factor analysis procedure.Participants were 334 help-seeking youth (age: 17.0 ± 3.3) from the Early Detection and Intervention for the Prevention of Psychosis Program, consisting of 203 participants at clinically higher risk (sum of P scores ≥ 7), 87 with clinically lower risk (sum of P scores < 7) and 44 in very early first-episode psychosis (<30 days of positive symptoms). Baseline SOPS data were subjected to principal axis factoring (PAF), estimating factors based on shared variance, with Oblimin rotation.PAF yielded four latent factors explaining 36.1% of total variance: positive symptoms; distress; negative symptoms; and deteriorated thought process. They showed reasonable internal consistency and good convergence validity, and were not orthogonal.The empirical factors of the SOPS showed similarities and notable differences compared with the existing SOPS structure. Regrouping the symptoms based on the empirical symptom dimensions may improve the diagnostic validity of the SOPS. Relative prominence of the factors and symptom frequency support early identification strategies focusing on positive symptoms and distress. Future investigation of long-term functional implications of these symptom factors may further inform intervention strategies.

    View details for DOI 10.1111/eip.12209

    View details for PubMedID 25529847